IZNN yields 20000000.00% · ABBV yields 3.06%● Live data
📍 IZNN pulled ahead of the other in Year 1
Combined, IZNN + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IZNN + ABBV for your $10,000?
IZON Network, Inc., a golf-centric technology and information-dissemination company, creates a golf technology platform in Canada and the United States. The company connects golfers to advertisers by installing multifunctional Web-enabled interactive tablets in golf cars that operate on and are owned by golf courses across the United States. Its Internet-connected interactive tablets provides a host of services to golfers and golf courses, such as GPS-based hole/course information, aerial views of fairways and green, accurate yardage information to hazards and greens, messaging, online scoring, and beverage cart ordering. The company also offers a portfolio of course management tools designed to enable course managers to improve player pace of play through GPS-based cart tracking and communications, increased merchandise, and concession sales through real-time on-tablet promotions, as well as access to additional revenue streams, such as sale of local advertising. In addition, it provides online marketing services. The company was formerly known as Digital Caddies, Inc. and changed its name to IZON Network, Inc. in September 2017. IZON Network, Inc. was incorporated in 2011 and is headquartered in Scottsdale, Arizona.
Full IZNN Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.